Brivaracetam is a third-generation antiepileptic racetam derivative and a 4-n-propyl analogue of levetiracetam. It is used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 time’s higher affinity than levetiracetam. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action. Brivaracetam received FDA approval on February 19, 2016
MODE OF ACTION:
While the exact mechanism of action of Brivaracetam is unknown, its anticonvulsant effects are believed to be due to its highly selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. The SV2A glycoprotein is a protein-coding gene implicated in synaptic signal transduction. It is believed to play a role in the regulation of neurotransmission by stimulating vesicle fusion and maintaining a reserve of secretory vesicles. Studies in SV2A-deficient animals have demonstrated an increased propensity for seizures. Brivaracetam’s actions as an SV2A ligand lend it broad-spectrum activity against POS.
- Adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age or older with epilepsy
16 years and older: 50 mg twice daily
Min. & Max. Maintenance Dosage: 25 mg to 100 mg twice daily
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.